Clinical Trial Update: Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating sintilimab in combination with IBI310 for EBV-positive gastric cancer/GEJ adenocarcinoma; efficacy and safety data are not yet detail…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric or Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• IBI310 (IBI310)
• Sintilimab (sintilimab)

Snippet

Sponsor: Peking University | Conditions: Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | Phase 1, Phase 2 | Status: UNKNOWN